FDA's REMS Stronghold: Industry Sees Need For Alternate Risk Management Plans Beyond Mandatory Programs
Executive Summary
As Risk Evaluation and Mitigation Strategies become more and more commonplace, industry is starting to balk at the use of the mandatory programs for every risk management activity
You may also be interested in...
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
Early REMS Assessments Show Room For Improvement In MedGuides
Results from early Risk Evaluation and Mitigation Strategy assessments suggest sponsors have a ways to go before they can show the vast majority of patients receive, read and understand Medication Guides.